Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3NET 2

Conditions

Carcinoma, Non-Small-Cell Lung 437Breast Neoplasms 382Neoplasms 291Prostatic Neoplasms 195Neoplasm Metastasis 155Multiple Myeloma 148Colorectal Neoplasms 124Lung Neoplasms 105Ovarian Neoplasms 102Parkinson Disease 4, Autosomal Dominant Lewy Body 98Melanoma 95Lymphoma, Follicular 94Recurrence 89Lymphoma, Non-Hodgkin 82Papillomavirus Infections 81Leukemia, Lymphocytic, Chronic, B-Cell 81Carcinoma, Hepatocellular 81Stomach Neoplasms 76Small Cell Lung Carcinoma 73Leukemia, Myeloid, Acute 70Pancreatic Neoplasms 67Pain 66Carcinoma, Renal Cell 65Uterine Cervical Neoplasms 64Keratosis, Actinic 63Urinary Bladder Neoplasms 59Lymphoma, Large B-Cell, Diffuse 53Myasthenia Gravis 52Leiomyoma 49Carcinoma 49

Interventions

lanreotide 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Serotonin Syndrome × Clear all
NCT07087054 2026-04-30

CAREFNDR

Crinetics Pharmaceuticals Inc.

Phase 3 Recruiting
141 enrolled
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT00774930 2022-10-14

ELECT

Ipsen

Phase 3 Completed
115 enrolled 17 charts
EndocrineNET

Carcinoid Tumor, Diarrhea, Flushing, Neuroendocrine Tumors, Serotonin Syndrome

NCT00092287 2020-04-30

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

Ipsen

Phase 3 Terminated
4 enrolled
Endocrine

Malignant Carcinoid Syndrome, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡